M Hrubisko

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

Heinz Gisslinger, Christoph Klade, Pencho Georgiev et al. · The Lancet Haematology · 2020 · 327 citations

Polycythaemia Vera, Hematology, Clinical Trials +5

Effects of Long-Term Intravenous Ibandronate Therapy on Skeletal-Related Events, Survival, and Bone Resorption Markers in Patients With Advanced Multiple Myeloma

Hans D. Menssen, A Sakalová, A Fontana et al. · Journal of Clinical Oncology · 2002 · 159 citations

Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial

Richard Greil, Petra Obrtlíková, Lukáš Smolej et al. · The Lancet Haematology · 2016 · 46 citations

Hematological Malignancy, Second-line Rituximab-containing Chemoimmunotherapy, Lymphoid Neoplasia +10

The role of metallothionein, glutathione, glutathione S-transferases and DNA repair in resistance to platinum drugs in a series of L1210 cell lines made resistant to anticancer platinum agents

M Hrubisko, Andrew McGown, Benjamin Fox · Biochemical Pharmacology · 1993 · 37 citations

Medicine, Platinum Agents, Anti-cancer Agent +5

Recommendations for the diagnosis and treatment of patients with polycythaemia vera

Antónia Hatalova, Mirjana Gotić, Miroslav Penka et al. · European Journal Of Haematology · 2018 · 13 citations